Introduction {#s1}
============

Fat redistribution, also called lipodystrophy, is frequently observed in patients on long term antiretroviral therapy (ART) [@pone.0063623-Carr1]. Some patients develop subcutaneous fat loss, or lipoatrophy; others gain fat, particularly in the breasts, dorsocervical fat pads, and viscerally. Individuals with mixed phenotypes of fat loss and fat gain also occur commonly. Fat redistribution is also associated with metabolic abnormalities, notably dyslipidaemia and insulin resistance, which increase the risk of cardiovascular disease [@pone.0063623-Grinspoon1].

Lipoatrophy has been associated with exposure to thymidine analogue nucleoside reverse transcriptase inhibitors (NRTIs) [@pone.0063623-McComsey1]. Central fat gain is also assumed to be an adverse drug reaction [@pone.0063623-Negredo1]. However, there is evidence that visceral abdominal fat in HIV-infected patients on ART is not increased relative to healthy controls [@pone.0063623-Bachetti1]. Untreated HIV infection eventually results in wasting, including loss of adipose tissue. Fat gain, which is widely prevalent in the general population and increases with age, may in part be the result of effective ART reversing fat loss due to HIV infection. It is important to determine whether lipodystrophy is an adverse drug reaction to avoid unnecessary drug substitutions which may result in risks of virologic failure, new toxicities, and undermining patient confidence if the lipodystrophy does not improve. Treatment adherence is compromised when patients believe they have lipodystrophy from antiretrovirals [@pone.0063623-Ammassari1].

If fat loss and fat gain were adverse antiretroviral drug reactions they would occur more commonly in HIV-infected patients on ART than in HIV-uninfected controls. Second, fat loss and/or fat gain would be associated with specific antiretroviral drugs or drug classes. Third, fat loss and/or fat gain would reverse after switching the identified antiretroviral drugs. We conducted a systematic review to test those three assumptions.

Methods {#s2}
=======

Eligibility criteria {#s2a}
--------------------

### Types of studies {#s2a1}

To answer the question 'Does fat loss and/or fat gain occur more commonly in patients on ART than in HIV-uninfected controls?' we included prospective cohort studies comparing HIV-infected patients with ART exposure to population controls either known or presumed to be HIV-uninfected. To answer the questions 'Is fat loss and/or fat gain associated with specific antiretroviral drugs?' we included randomised controlled trials comparing antiretroviral regimens. To answer the question 'Is fat loss and/or fat gain reversed after switching antiretroviral drugs?' we included studies where participants with virologic suppression were randomised to continue their current ART regimen or switch to an alternative regimen.

### Participants {#s2a2}

We included both ART-naïve and ART-experienced HIV-infected patients who were at least 12 years old. For the cohort studies we included control participants who were presumed to be HIV-uninfected. We excluded studies with fewer than 20 participants in any arm.

### Interventions {#s2a3}

We included studies that used any antiretroviral regimens, given for at least 24 weeks, with the exception of those containing hydroxyurea.

### Outcome measures {#s2a4}

We included studies with at least one objective measure of fat distribution done at baseline, and repeated at least once, at a minimum of 24 weeks after baseline. Objective methods of measuring fat distribution included: dual-energy x-ray absorptiometry (DEXA), computerized tomography (CT), or magnetic resonance imaging (MRI). We included measures done both as primary or secondary outcomes, and in the whole study population, or within a sub-study. Specific outcomes included:

To assess fat loss:

-   Change from baseline in limb fat

-   Change from baseline in subcutaneous adipose tissue (SAT)

-   Proportion with ≥20% loss in limb fat

-   Proportion with ≥20% loss in SAT

To assess fat gain:

-   Change from baseline in trunk fat

-   Change from baseline in visceral adipose tissue (VAT)

-   Proportion with ≥20% gain in trunk fat

-   Proportion with ≥20% gain in VAT.

Search strategies {#s2b}
-----------------

We searched two electronic journal databases, PubMed and EMBASE, for articles published between 1 January 1990 and 7 July 2011. We hand-searched electronic databases for the Conferences on Retroviruses and Opportunistic Infections and the International AIDS Society conferences, from 2001. There was no language restriction, provided that an English translation of the abstract was available. The PubMed search strategy terms were as follows:

HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tw\] OR hiv-1\*\[tw\] OR hiv-2\*\[tw\] OR hiv1\[tw\] OR hiv2\[tw\] OR hiv infect\*\[tw\] OR human immunodeficiency virus\[tw\] OR human immunedeficiency virus\[tw\] OR human immuno-deficiency virus\[tw\] OR human immune-deficiency virus\[tw\] OR ((human immun\*) AND (deficiency virus\[tw\])) OR acquired immunodeficiency syndrome\[tw\] OR acquired immunedeficiency syndrome\[tw\] OR acquired immuno-deficiency syndrome\[tw\] OR acquired immune-deficiency syndrome\[tw\] OR ((acquired immun\*) AND (deficiency syndrome\[tw\])) OR "sexually transmitted diseases, viral"\[MH:noexp\]

AND

Search Antiretroviral Therapy, Highly Active\[MeSH\] OR Anti-Retroviral Agents\[MeSH\] OR Antiviral Agents\[MeSH:NoExp\] OR ((anti) AND (hiv\[tw\])) OR antiretroviral\*\[tw\] OR ((anti) AND (retroviral\*\[tw\])) OR HAART\[tw\] OR ((anti) AND (acquired immunodeficiency\[tw\])) OR ((anti) AND (acquired immunedeficiency\[tw\])) OR ((anti) AND (acquired immuno-deficiency\[tw\])) OR ((anti) AND (acquired immune-deficiency\[tw\])) OR ((anti) AND (acquired immun\*) AND (deficiency\[tw\]))

OR

Search zalcitabine OR zidovudine OR lamivudine OR stavudine OR didanosine OR tenofovir OR abacavir OR emtricitabine OR nevirapine OR efavirenz OR delavirdine OR etravirine OR rilpivirine OR amprenavir OR atazanavir OR tipranavir OR indinavir OR saquinavir OR lopinavir OR fosamprenavir OR ritonavir OR darunavir OR nelfinavir OR enfurvirtide OR maraviroc OR raltegravir

AND

Search Lipodystrophy\[mh\] OR lipodystrophy\[tiab\] OR lypodystrophy\[tiab\] OR lipodystrophies\[tiab\] OR lipohypertrophy\[tiab\] OR lipoatrophy\[tiab\] OR body fat distribution\[mh\] OR fat\[tiab\] OR fats\[tiab\] OR abdominal fat\[mh\] OR adipose tissue\[mh\] OR adipose \[tiab\] OR adiposity\[tiab\] OR temporal wasting\[tiab\] OR buffalo hump\[tiab\].

Data collection {#s2c}
---------------

Two authors (RdW and KC) independently reviewed all study abstracts identified by the search strategy, using a specially designed eligibility form. We obtained the full articles, conference abstracts or conference posters for all studies that met the inclusion criteria. An independent translator reviewed articles that were published in languages other than English. We resolved disagreements as to study eligibility through consensus and discussion with the third author (GM) if necessary. One author (RdW) extracted data using a data extraction form; another author (KC) checked the extracted data. Two authors (RdW and KC) assessed the risk of bias of all included studies [@pone.0063623-Higgins1].

Results {#s3}
=======

We identified a total of 27 studies for inclusion in the review: one cohort study comparing HIV-infected patients with controls [@pone.0063623-Grunfeld1]; 18 randomised controlled trials comparing antiretroviral regimens [@pone.0063623-McComsey1], [@pone.0063623-Negredo1], [@pone.0063623-Kolta1]--[@pone.0063623-Jemsek1]; seven switching studies [@pone.0063623-Moyle2]--[@pone.0063623-Ruiz1]; and one study that fulfilled the criteria for both randomised controlled trials and switching studies [@pone.0063623-Tebas2]. Our search of PubMed and Embase databases identified 3031 potential abstracts. We identified a further 67 articles through conference databases or other sources. After removing duplicate records, we screened 3042 abstracts and excluded 2966 as they did not meet our inclusion criteria. We retrieved and assessed the full text articles for the remaining 76, and excluded 49 that did not meet our inclusion criteria (see [Figure 1](#pone-0063623-g001){ref-type="fig"} and [Table S1](#pone.0063623.s001){ref-type="supplementary-material"}). We assessed two articles that were published in Spanish through means of a translator. We included the full text articles for five studies that we identified through conference abstracts.

![Flow diagram of study selection.](pone.0063623.g001){#pone-0063623-g001}

Characteristics of included studies {#s3a}
-----------------------------------

Fat distribution measures were done in all participants for 15 studies: one cohort study [@pone.0063623-Grunfeld1]; nine randomised controlled trials comparing antiretroviral regimens [@pone.0063623-Negredo1], [@pone.0063623-vanVonderen1], [@pone.0063623-Haubrich1], [@pone.0063623-McComsey2], [@pone.0063623-Martin1], [@pone.0063623-Duvivier1], [@pone.0063623-Cameron1], [@pone.0063623-Moyle1], [@pone.0063623-Tebas2]; and five switching studies [@pone.0063623-Moyle2], [@pone.0063623-Feeney1], [@pone.0063623-Valantin2]--[@pone.0063623-Ruiz1]. They were done in a subset of participants only in the remaining 12 studies [@pone.0063623-McComsey1], [@pone.0063623-Kolta1]--[@pone.0063623-Valantin1], [@pone.0063623-Martinez1], [@pone.0063623-Carr2], [@pone.0063623-Tebas1], [@pone.0063623-Podzamczer1], [@pone.0063623-Jemsek1], [@pone.0063623-Curran1], [@pone.0063623-Fisher1], [@pone.0063623-Dube2]. The characteristics of the included studies are summarised in [Table 1](#pone-0063623-t001){ref-type="table"}, and risk of bias assessment in [Table S2](#pone.0063623.s002){ref-type="supplementary-material"}.

10.1371/journal.pone.0063623.t001

###### Characteristics of included studies.

![](pone.0063623.t001){#pone-0063623-t001-1}

  Study                                           Year published   DEXA/CT/MRI population    n    ART experience                    Lipodystrophy                     Age group    Duration of follow up             Primary endpoint(s)
  ---------------------------------------------- ---------------- ------------------------ ----- ---------------- -------------------------------------------------- ------------ ----------------------- -----------------------------------------
  [@pone.0063623-Grunfeld1]                            2010             Whole study         691    Experienced     Patients with and without lipodystrophy included   ≥18 years           5 years                         SAT, VAT
  [@pone.0063623-McComsey1]                            2011              Sub-study          269       Naïve                               NA                          ≥16 years          192 weeks                   Lipoatrophy (DEXA)
  [@pone.0063623-Kolta1]                               2011              Sub-study          63        Naïve                               NA                              NR             96 weeks                         Efficacy
  [@pone.0063623-Lennox1]                              2010              Sub-study          112       Naïve                               NA                          ≥18 years          96 weeks                         Efficacy
  [@pone.0063623-Valantin1]                            2010              Sub-study          156    Experienced                            NR                          ≥18 years          48 weeks                         Efficacy
  [@pone.0063623-Negredo1]                             2009             Whole study         66     Experienced                            NR                          ≥18 years          48 weeks                   Mitochondrial changes
  [@pone.0063623-vanVonderen1]                         2009             Whole study         48        Naïve                               NA                            18--70           24 months                      LF, SAT, VAT
  [@pone.0063623-Haubrich1]                            2009             Whole study         757       Naïve                               NA                          ≥13 years          96 weeks                    Lipoatrophy (DEXA)
  [@pone.0063623-Martinez1]                            2009              Sub-study          47     Experienced     Patients with and without lipodystrophy included     Adult            48 weeks                         Efficacy
  [@pone.0063623-McComsey2]                            2009             Whole study         200       Naïve                               NA                            Adult            96 weeks                    Efficacy and safety
  [@pone.0063623-Tebas2]                               2009             Whole study         101    Experienced                Self-reported lipoatrophy                   NR             48 weeks                            STF
  [@pone.0063623-Martin1]                              2009             Whole study         357    Experienced                            NR                          ≥18 years          96 weeks                         Efficacy
  [@pone.0063623-Carr2]                                2008              Sub-study          140       Naïve                               NA                          ≥18 years          48 weeks                            LF
  [@pone.0063623-Duvivier1]                            2008             Whole study         117       Naïve                               NA                          ≥18 years          96 weeks                      LF at 96 weeks
  [@pone.0063623-Cameron1]                             2008             Whole study         155       Naïve                               NA                              NR             96 weeks                         Efficacy
  [@pone.0063623-Dube1], [@pone.0063623-Dube2]         2007              Sub-study          157       Naïve                               NA                              NR             144 weeks         Changes in glucose and lipid metabolism
  [@pone.0063623-Tebas1]                               2007              Sub-study          62     Experienced     Patients with and without lipodystrophy included       NR            \>96 weeks                           LF
  [@pone.0063623-Podzamczer1]                          2007              Sub-study          57        Naïve                               NA                            Adult            96 weeks                   Clinical lipoatrophy
  [@pone.0063623-Moyle1]                               2006             Whole study         105    Experienced                       Lipoatrophy                      ≥18 years          48 weeks                            LF
  [@pone.0063623-Jemsek1]                              2006              Sub-study          211       Naïve                               NA                          ≥16 years          48 weeks                            VAT
  [@pone.0063623-Moyle2]                               2012             Whole study         200    Experienced                Abdominal fat accumulation              ≥18 years          96 weeks                           TF:LF
  [@pone.0063623-Curran1]                              2012              Sub-study          74     Experienced                            NR                          ≥18 years          48 weeks                            VAT
  [@pone.0063623-Feeney1]                              2011             Whole study         142    Experienced                            NR                            Adult            48 weeks                            LF
  [@pone.0063623-Fisher1]                              2009              Sub-study          100    Experienced                            NR                          ≥18 years          48 weeks                   Change in haemoglobin
  [@pone.0063623-Valantin2]                            2008             Whole study         100    Experienced                Self-reported lipoatrophy               ≥18 years          96 weeks                            STF
  [@pone.0063623-Carr3]                                2002             Whole study         106    Experienced                   Clinical lipoatrophy                 \>18 years         24 weeks                            LF
  [@pone.0063623-Ruiz1]                                2001             Whole study         106    Experienced                  Clinical lipodystrophy                  Adult            48 weeks                         Efficacy

LF: limb fat; NA: not applicable -- treatment-naïve patients; NR: not reported; SAT: subcutaneous adipose tissue; STF: subcutaneous thigh fat; TF: trunk fat; VAT: visceral adipose tissue.

Participants {#s3b}
------------

Twelve randomised controlled trials enrolled antiretroviral-naïve participants [@pone.0063623-McComsey1], [@pone.0063623-Kolta1], [@pone.0063623-Lennox1], [@pone.0063623-vanVonderen1], [@pone.0063623-Haubrich1], [@pone.0063623-McComsey2], [@pone.0063623-Carr2]--[@pone.0063623-Cameron1], [@pone.0063623-Podzamczer1], [@pone.0063623-Jemsek1], [@pone.0063623-Dube2]. The cohort study [@pone.0063623-Grunfeld1], seven randomised controlled trials [@pone.0063623-Negredo1], [@pone.0063623-Valantin1], [@pone.0063623-Martinez1], [@pone.0063623-Martin1], [@pone.0063623-Tebas1], [@pone.0063623-Moyle1], [@pone.0063623-Tebas2], and all the switching studies enrolled antiretroviral-experienced participants. The cohort study enrolled participants both with and without lipodystrophy. Two randomised controlled trials enrolled only participants with clinical or self-reported features of lipoatrophy [@pone.0063623-Moyle1], [@pone.0063623-Tebas2]; and two enrolled participants both with and without lipoatrophy [@pone.0063623-Martinez1], [@pone.0063623-Tebas1]. Three switching studies enrolled only participants with clinical or self-reported lipoatrophy [@pone.0063623-Valantin2]--[@pone.0063623-Ruiz1]; and one enrolled participants with features of abdominal fat accumulation, defined as a waist-to-hip ratio of \>0.9, with a waist circumference \>88.2 or \>75.3 cm in men and women respectively [@pone.0063623-Moyle2]. For the remaining studies it was not reported whether or not participants had features of lipodystrophy at baseline.

Interventions {#s3c}
-------------

All included studies involved a comparison of different antiretroviral regimens, with the exception of the cohort study that compared HIV-infected people with people who were known or presumed to be HIV-uninfected [@pone.0063623-Grunfeld1]. Eight randomised controlled trials [@pone.0063623-Negredo1], [@pone.0063623-Kolta1], [@pone.0063623-Valantin1]--[@pone.0063623-Haubrich1], [@pone.0063623-Duvivier1], [@pone.0063623-Tebas1], [@pone.0063623-Tebas2], and two switching studies [@pone.0063623-Valantin2], [@pone.0063623-Tebas2] evaluated NRTI-sparing regimens; four randomised controlled trials [@pone.0063623-McComsey1], [@pone.0063623-Cameron1], [@pone.0063623-Jemsek1], [@pone.0063623-Dube2], and one switching study [@pone.0063623-Ruiz1] evaluated protease inhibitor (PI) versus non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens; six randomised controlled trials [@pone.0063623-McComsey1], [@pone.0063623-Martinez1], [@pone.0063623-Martin1], [@pone.0063623-Podzamczer1], [@pone.0063623-Moyle1], [@pone.0063623-Dube2], and five switching studies [@pone.0063623-Feeney1], [@pone.0063623-Fisher1], [@pone.0063623-Carr3], [@pone.0063623-Tebas2], [@pone.0063623-Milinkovic1] evaluated NRTI versus NRTI regimens; two randomised controlled trials [@pone.0063623-McComsey2], [@pone.0063623-Carr2], and one switching study [@pone.0063623-Moyle2] evaluated PI versus PI regimens; and one randomised controlled trial [@pone.0063623-Lennox1], and one switching study [@pone.0063623-Curran1] evaluated other antiretroviral categories.

Outcomes {#s3d}
--------

An objective measure of fat distribution was the primary study endpoint in 15 studies [@pone.0063623-McComsey1], [@pone.0063623-Grunfeld1], [@pone.0063623-vanVonderen1], [@pone.0063623-Haubrich1], [@pone.0063623-Carr2], [@pone.0063623-Duvivier1], [@pone.0063623-Tebas1], [@pone.0063623-Moyle1]--[@pone.0063623-Feeney1], [@pone.0063623-Valantin2], [@pone.0063623-Carr3], [@pone.0063623-Tebas2]. In the remaining studies, measures of fat distribution were secondary endpoints.

### HIV-infected patients compared with healthy controls {#s3d1}

The FRAM2 study compared fat distribution in HIV-infected patients with healthy controls, using MRI at two time-points separated by about five years [@pone.0063623-Grunfeld1]. The control participants were recruited from the Visceral Fat and Metabolic Rate in Young Adults sub-study of the Coronary Artery Risk Development in Young Adults study. They were selected as they had previous experience of fat distribution investigations, and had a similar age and ethnic distribution to most HIV-infected patients in the United States [@pone.0063623-Tien1]. Although the analyses included HIV-infected patients who had never been on ART (11.8% at baseline and 5.7% at year 5), we included the study as only a small minority were not on ART. Sub-group analyses by ART status were not done.

There was clear evidence of fat loss in HIV-infected people, 53% of whom had lipoatrophy (defined as leg SAT below the 10^th^ percentile of controls) after five years of observation. Longer duration of stavudine use was associated with less leg SAT. After five years there was significantly less SAT at all sites in HIV-infected men, but only in the limbs in HIV-infected women. Multivariable analysis showed that increase in SAT over five years was less in HIV-infected people at all sites except the lower trunk.

By contrast, there was no evidence of regional fat accumulation in HIV-infected people. After five years the amount of trunk SAT and VAT was similar in HIV-infected and control women, while HIV-infected men had less fat at all sites than control men. The gains in VAT over five years were similar in HIV-infected people and controls.

### Fat loss: changes in limb fat and SAT with different antiretroviral regimens {#s3d2}

The changes from baseline in limb fat and SAT are summarised in [Tables 2](#pone-0063623-t002){ref-type="table"}, [3](#pone-0063623-t003){ref-type="table"}, [4](#pone-0063623-t004){ref-type="table"}, [5](#pone-0063623-t005){ref-type="table"}, and [6](#pone-0063623-t006){ref-type="table"}, and the incidences of peripheral lipoatrophy (defined as ≥20% loss in limb fat) are summarised in [Tables 7](#pone-0063623-t007){ref-type="table"}, [8](#pone-0063623-t008){ref-type="table"}, [9](#pone-0063623-t009){ref-type="table"}, [10](#pone-0063623-t010){ref-type="table"}, and [11](#pone-0063623-t011){ref-type="table"}.

10.1371/journal.pone.0063623.t002

###### Change from baseline in limb fat (LF) on DEXA scan, and subcutaneous thigh fat (STF) and subcutaneous adipose tissue (SAT) on CT scan: NRTI-containing regimens versus NRTI-sparing regimens.

![](pone.0063623.t002){#pone-0063623-t002-2}

  Study                           Measure               Arm                                  Week 48 (n)                             p value                     Week 96 (n)                     p value
  ------------------------------ --------- ------------------------------ -------------------------------------------------- ------------------------ --------------------------------- -------------------------
  [@pone.0063623-Kolta1]           LF^a^            LPVr+AZT+3TC                             −703 g (22)                              0.014                      −1930 g (5)                     \>0.05
                                                  LPVr monotherapy                            −63 g (41)                                                         −400 g (8)             
  [@pone.0063623-Negredo1]                                                      Percentage of body fat, 0 & 48 wks:^c^                                                                  
                                  LF^a,b^      LPVr+ continue 2NRTIs                      12.2; 13.4 (33^d^)                            NR                           ND                            NA
                                                      NVP+LPVr                            11.1; 14.1 (33^d^)                                                         ND                 
  [@pone.0063623-vanVonderen1]                                                     Mean (95% CI) g, 0 & 48 wks:^f^                                       Mean (95% CI) g, 96 wks:^f^    
                                   LF^e^            AZT+3TC+LPVr           6360 (5919 to 6801); 6520 (6059 to 6981) (22^d^)             NR                   5980 (5519 to 6441)                   NR
                                                      NVP+LPVr             6360 (5968 to 6752); 7030 (6618 to 7442) (26^d^)                                  7210 (6789 to 7631)        
                                                                                 Mean (95% CI) cm^2^, 0 & 48 wks:^f^                                   Mean (95% CI) cm^2^, 96 wks:^f^  
                                  SAT^e^            AZT+3TC+LPVr              118 (107 to 129); 126 (114 to 138) (22^d^)                NR                    123 (111 to 135)                     NR
                                                      NVP+LPVr                118 (108 to 128); 132 (121 to 143) (26^d^)                                      142 (131 to 153)          
  [@pone.0063623-Haubrich1]        LF^a^    EFV+3TC+(TDF or AZT or D4T)                     8.9%^g^ (188)                               NR                       1.4% (171)              \<0.001 vs NRTI-sparing
                                            LPVr+3TC+(TDF or AZT or D4T)                    10.1%^g^ (191)                                                       9.8% (166)               0.013 vs NRTI-sparing
                                              EFV+LPVr (NRTI-sparing)                       14.2%^g^ (197)                                                       17.6% (173)            
  [@pone.0063623-Tebas2]          STF^a^      ABC+continue other ARVs                          18% (42)                                0.57                          ND                            NA
                                                      LPVr+NVP                                 17% (46)                                                              ND                 
                                  SAT^a^      ABC+continue other ARVs                          29% (43)                                0.6                           ND                            NA
                                                      LPVr+NVP                                 33% (47)                                                              ND                 
  [@pone.0063623-Duvivier1]        LF^e^             PIr+2NRTIs                              0.37 kg (28)                       0.253 vs NNRTI+PIr                   ND                            NA
                                                    NNRTI+2NRTIs                             0.9 kg (21)                      0.298^h^ vs PIr+2NRTIs                 ND                            NA
                                                     NNRTI+PIr                               0.79 kg (49)                      0.793 vs NRTI+2NRTIs                  ND                            NA
  [@pone.0063623-Tebas1]           LF^a^           EFV+2NRTIs^i^                             −242 g (25)                              0.086                    −850 g (25)^j^                     0.002
                                                      LPVr+EFV                                562 g (22)                                                        782 g (22)^j^           
  [@pone.0063623-Valantin1]        LF^a^       DRVr+ continue 2NRTIs                         −0.26% (74)                             \<0.001                         ND                            NA
                                                  DRVr monotherapy                            8.3% (67)                                                              ND                            NA

a\. median; b. leg fat; c. absolute values at each time-point (change from baseline not reported); d. n at baseline (n at time-point not reported); e. mean; f. means (corrected for differences in baseline values) and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from baseline not reported); g. values derived from graph; h. calculated by authors of this review; i. DDI+3TC or DDI+AZT or AZT+3TC or D4T+ 3TC or DDI+D4T; j. at last visit (median 102 weeks).

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DRVr: ritonavir-boosted darunavir; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; NVP: nevirapine; PIr: ritonavir-boosted PI; TDF: tenofovir.

10.1371/journal.pone.0063623.t003

###### Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: PI versus NNRTI.

![](pone.0063623.t003){#pone-0063623-t003-3}

  Study                                           Measure                  Arm                                        Week 48 (n)                         p value    Week 96 (n)     p value
  ---------------------------------------------- --------- ------------------------------------ -------------------------------------------------------- --------- ---------------- ---------
  [@pone.0063623-McComsey1]                        LF^a^        ATVr+(ABC+3TC or TDF+FTC)                            25.2%^b^ (105)                         NR        30.4% (94)      0.01
                                                                 EFV+(ABC+3TC or TDF+FTC)                            17.7%^b^ (112)                                  16.5% (109)    
  [@pone.0063623-Haubrich1]                        LF^c^       LPVr+3TC+(TDF or AZT or D4T)                          10.1%^b^ (191)                                   9.8% (166)      0.007
                                                               EFV+3TC+(TDF or AZT or D4T)                           8.9%^b^ (188)                          NR        1.4% (171)    
  [@pone.0063623-Duvivier1]                        LF^a^                PIr+2NRTIs                                    0.37 kg (28)                        0.30^d^         ND           NA
                                                                       NNRTI+2NRTIs                                   0.9 kg (21)                                         ND           NA
  [@pone.0063623-Cameron1]                         LF^c^    LPVr+AZT+3TC or LPV monotherapy^e^                         11.8% (NR)                           NR      18.5%^b^ (74)      NR
                                                                       EFV+AZT+3TC                                     3.1% (NR)                            NR       −9%^b^ (32)    
  [@pone.0063623-Jemsek1]                         SAT^a^               ATV+AZT+3TC               12.8 cm^2b^ (62). 95% CI for difference: −16.8 to 27.5     NR            ND           NA
                                                                       EFV+AZT+3TC                                  7.6 cm^2b^ (47)                                       ND           NA
  [@pone.0063623-Dube1], [@pone.0063623-Dube2]    LF^c,f^        NFV+(AZT+3TC or DDI+D4T)                            −4.7%^b^ (23)                          NR      −23.7%^b^ (11)     NR
                                                                 EFV+(AZT+3TC or DDI+D4T)                             1.5%^b^ (26)                                   9.9%^b^ (16)   

a\. mean; b. values derived from graph; c. median; d. calculated by authors of this review; e. if virologically suppressed for 3 months; f. as-treated analysis.

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC: emtricitabine; LPVr: ritonavir-boosted lopinavir; NFV: nelfinavir; TDF: tenofovir.

10.1371/journal.pone.0063623.t004

###### Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: NRTI versus NRTI.

![](pone.0063623.t004){#pone-0063623-t004-4}

  Study                                           Measure               Arm                  Week 48 (n)      p value    Week 96 (n)     p value
  ---------------------------------------------- --------- ------------------------------ ------------------ --------- ---------------- ---------
  [@pone.0063623-McComsey1]                        LF^a^       ABC+3TC+(ATVr or EFV)        22.8%^b^ (107)      NR       24.9% (102)      0.46
                                                               TDF+FTC+(ATVr or EFV)        19.7%^b^ (110)               20.9% (101)    
  [@pone.0063623-Martinez1]                        LF^c^    ABC+3TC+continue PI or NNRTI      104 g (23)       0.92           ND           NA
                                                            TDF+FTC+continue PI or NNRTI      75 g (24)                       ND           NA
  [@pone.0063623-Podzamczer1]                      LF^a^            ABC+3TC+EFV               686 g (25)       0.001      913 g (25)     \<0.001
                                                                    D4T+3TC+EFV              −1164 g (32)                −1578 g (32)   
  [@pone.0063623-Moyle1]                           LF^a^      ABC+continue other ARVs         483 g (44)       0.37           ND           NA
                                                              TDF+continue other ARVs         329 g (49)                      ND           NA
                                                  SAT^a^      ABC+continue other ARVs       8.0 cm^2^ (44)     0.96           ND           NA
                                                              TDF+continue other ARVs       8.4 cm^2^ (49)                    ND           NA
  [@pone.0063623-Dube1], [@pone.0063623-Dube2]    LF^c,d^       DDI+D4T+(EFV or NFV)        −11.9%^b^ (42)      NR      −26.4%^b^ (22)     NR
                                                                AZT+3TC+(EFV or NFV)         1.6%^b^ (39)                1.7%^b^ (24)   
  [@pone.0063623-Martin1]                          LF^a^    ABC+3TC+continue NNRTI or PI   0.3 kg (179^e^)      0.4      0.53 kg (NR)     0.46
                                                            TDF+FTC+continue NNRTI or PI   0.19 kg (178^e^)              0.42 kg (NR)   

a\. mean; b. values derived from graph; c. median; d. as-treated analysis; e. n at baseline (n at time-point not reported).

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC: emtricitabine; NFV: nelfinavir; TDF: tenofovir.

10.1371/journal.pone.0063623.t005

###### Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: PI versus PI.

![](pone.0063623.t005){#pone-0063623-t005-5}

  Study                        Measure         Arm           Week 48 (n)           p value          Week 96 (n)   p value
  --------------------------- --------- ----------------- ----------------- ---------------------- ------------- ---------
  [@pone.0063623-McComsey2]     LF^a^     ATVr+D4T+3TC         2% (72)                NR             −9% (55)     \>0.05
                                           ATV+D4T+3TC        −3% (89)                               −17% (67)   
                               SAT^a^     ATVr+D4T+3TC        12% (68)                NR              8% (56)     \>0.05
                                           ATV+D4T+3TC        12% (85)                                2% (62)    
  [@pone.0063623-Carr2]         LF^b^    TPVr100+TDF+3TC      1.4% (46)      0.02 vs LPVr+TDF+3TC       ND          NA
                                         TPVr200+TDF+3TC      1.6% (48)      0.14 vs LPVr+TDF+3TC       ND          NA
                                          LPVr+TDF+3TC        2.8% (45)                                 ND          NA
                               SAT^b^    TPVr100+TDF+3TC   −2.1 cm^2^ (46)   0.03 vs LPVr+TDF+3TC       ND          NA
                                         TPVr200+TDF+3TC   4.2 cm^2^ (48)    0.13 vs LPVr+TDF+3TC       ND          NA
                                          LPVr+TDF+3TC     17.6 cm^2^ (45)                              ND          NA

a\. mean; b. median.

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; D4T: stavudine; LPVr: ritonavir-boosted lopinavir; TDF: tenofovir; TPVr100: tipranavir/ritonavir 500/100 mg twice a day; TPVr200: tipranavir/ritonavir 500/200 mg twice a day.

10.1371/journal.pone.0063623.t006

###### Change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: raltegravir versus efavirenz.

![](pone.0063623.t006){#pone-0063623-t006-6}

  Study                      Measure       Arm        Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------- --------- -------------- ------------- --------- ------------- ---------
  [@pone.0063623-Lennox1]     LF^a^    RAL+TDF +FTC   18.1% (40)    0.95^b^   18.2% (37)    0.88^b^
                                       EFV+TDF +FTC   17.7% (46)              17.0% (38)   

a\. mean; b. p value calculated by authors of this review.

Antiretrovirals: EFV: efavirenz; FTC: emtricitabine; RAL: raltegravir; TDF: tenofovir.

10.1371/journal.pone.0063623.t007

###### Proportion of patients with peripheral lipoatrophy on DEXA scan: NRTI-containing regimens versus NRTI-sparing regimens.

![](pone.0063623.t007){#pone-0063623-t007-7}

  Study                           Definition                  Arm                                           Week 48 (n)                              p value   Week 96 (n)           p value
  --------------------------- ------------------ ------------------------------ ------------------------------------------------------------------- --------- ------------- -------------------------
  [@pone.0063623-Kolta1]       \>20% loss of LF           LPVr+AZT+3TC                                      27.3% (22)                                0.018        ND                  NA
                                                        LPVr monotherapy                                     4.9% (41)                                             ND       
                                                                                 OR^a^ LPVr+AZT+3TC vs LPVr monotherapy 7.06. 95% CI 1.11 to 78.69                          
  [@pone.0063623-Haubrich1]    ≥20% loss of LF    EFV+3TC+(TDF or AZT or D4T)                                21% (188)                                 NR       32% (171)    \<0.001 vs NRTI-sparing
                                                  LPVr+3TC+(TDF or AZT or D4T)                               10% (191)                                          17% (166)     0.023 vs NRTI-sparing
                                                    EFV+LPVr (NRTI-sparing)                                  7% (197)                                           9% (173)    
  [@pone.0063623-Valantin1]    \>20% loss of LF      DRVr+ continue 2NRTIs                                  10.8% (74)                                0.035        ND                  NA
                                                        DRVr monotherapy                                     1.5% (67)                                             ND                  NA

a\. adjusted for age and sex.

LF: limb fat; NA: not applicable; ND: not done; NR: not reported; OR: odds ratio.

Antiretrovirals: 3TC: lamivudine; AZT: zidovudine; D4T: stavudine; DRVr: ritonavir-boosted darunavir; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; TDF: tenofovir.

10.1371/journal.pone.0063623.t008

###### Proportion of patients with peripheral lipoatrophy on DEXA scan: PI versus NNRTI.

![](pone.0063623.t008){#pone-0063623-t008-8}

  Study                           Definition                      Arm                       Week 48 (n)       p value                   Week 96 (n)                   p value
  --------------------------- ------------------ ------------------------------------- --------------------- --------- --------------------------------------------- ---------
  [@pone.0063623-Haubrich1]    ≥20% loss of LF       LPVr+3TC+(TDF or AZT or D4T)            10% (191)          NR                       17% (166)                     0.003
                                                      EFV+3TC+(TDF or AZT or D4T)            21% (188)                                   32% (171)                   
                                                                                                                        OR^a^ EFV vs LPVr 2.63. 95% CI 1.49 to 4.64   \<0.001
  [@pone.0063623-Cameron1]     \>20% loss of LF   LPVr+AZT+3TC or LPVr monotherapy^b^           ND              NA                        5% (74)                     \<0.001
                                                              EFV+AZT+3TC                       ND                                       34% (32)                    
  [@pone.0063623-Dube2]        \>10% loss of LF        NFV+(AZT+3TC or DDI+D4T)                 NR                                                                   
                                                       EFV+(AZT+3TC or DDI+D4T)                 NR                                          ND                          NA
                                                                                        OR^c^ NFV vs EFV NR    0.06                                                  

a\. adjusted for NRTI arm, race, sex, age, baseline extremity fat and baseline CD4 count; b. if virologically suppressed for 3 months; c. adjusted for NRTI assignment, age, sex, race, and baseline BMI, HIV RNA and CD4 count.

LF: limb fat; NA: not applicable; ND: not done; NR: not reported; OR: odds ratio.

Antiretrovirals: 3TC: lamivudine; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; NFV: nelfinavir; TDF: tenofovir.

10.1371/journal.pone.0063623.t009

###### Proportion of patients with peripheral lipoatrophy on DEXA scan: NRTI versus NRTI.

![](pone.0063623.t009){#pone-0063623-t009-9}

  Study                       Definition              Arm                              Week 48 (n)                     p value   Week 96 (n)   p value
  ----------------------- ------------------ ---------------------- ------------------------------------------------- --------- ------------- ---------
  [@pone.0063623-Dube2]    \>10% loss of LF   DDI+D4T+(EFV or NFV)                         NR                                                 
                                              AZT+3TC+(EFV or NFV)                         NR                                        ND          NA
                                                                     OR^a^ DDI+D4T vs AZT+3TC 3.3. 95% CI 1.2 to 8.6    0.02                  

a\. adjusted for age, sex, race, and baseline BMI, HIV RNA and CD4 count.

LF: limb fat; NA: not applicable; ND: not done; NR: not reported; OR: odds ratio.

Antiretrovirals: 3TC: lamivudine; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; NFV: nelfinavir.

10.1371/journal.pone.0063623.t010

###### Proportion of patients with peripheral lipoatrophy on DEXA scan: PI versus PI.

![](pone.0063623.t010){#pone-0063623-t010-10}

  Study                          Definition           Arm        Week 48 (n)   p value   Week 96 (n)   p value
  --------------------------- ----------------- --------------- ------------- --------- ------------- ---------
  [@pone.0063623-McComsey2]    ≥20% loss of LF   ATVr+D4T +3TC    21% (72)       NR       29% (55)     \<0.05
                                                 ATV+D4T +3TC     30% (89)                49% (67)    

LF: limb fat; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; D4T: stavudine.

10.1371/journal.pone.0063623.t011

###### Proportion of patients with peripheral lipoatrophy on DEXA scan: raltegravir versus efavirenz.

![](pone.0063623.t011){#pone-0063623-t011-11}

  Study                        Definition          Arm        Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------- ----------------- -------------- ------------- --------- ------------- ---------
  [@pone.0063623-Lennox1]    ≥20% loss of LF   RAL+TDF +FTC       ND          NA        8% (37)     0.62^a^
                                               EFV+TDF +FTC       ND                    5% (38)    

a\. p value calculated by the authors of this review.

LF: limb fat; NA: not applicable; ND: not done.

Antiretrovirals: EFV: efavirenz; FTC: emtricitabine; RAL: raltegravir; TDF: tenofovir.

In general, participants who received NRTI-sparing regimens gained more (or lost less) SAT or limb fat over time than those on NRTI-containing regimens. However one study that compared an abacavir-containing regimen with an NRTI-sparing regimen found no significant between-arm differences in change in subcutaneous thigh fat or SAT [@pone.0063623-Tebas2]. Participants who received PI-containing regimens also gained more (or lost less) SAT or limb fat over time than those on efavirenz-based regimens [@pone.0063623-McComsey1], [@pone.0063623-Haubrich1], [@pone.0063623-Cameron1], [@pone.0063623-Jemsek1], [@pone.0063623-Dube2]. The incidence of peripheral lipoatrophy (defined as ≥20% loss of limb fat) was significantly lower in participants on NRTI-sparing regimens compared with those on NRTI-containing regimens, and in those on PI-containing regimens compared with those on EFV-based regimens [@pone.0063623-Kolta1], [@pone.0063623-Valantin1], [@pone.0063623-Haubrich1], [@pone.0063623-Cameron1].

There were no significant differences in average gains in SAT or limb fat over time in the four studies that compared abacavir- with tenofovir-based regimens [@pone.0063623-McComsey1], [@pone.0063623-Martinez1], [@pone.0063623-Martin1], [@pone.0063623-Moyle1]. One study found that participants who received an abacavir-containing regimen gained limb fat over time, in contrast to participants who received a stavudine-containing regimen who lost limb fat over time (gain of 913 g versus loss of 1578 g, p\<0.001) [@pone.0063623-Podzamczer1]. Another study found that participants who received a zidovudine-lamivudine-containing regimen gained limb fat over time, in contrast to participants who received a stavudine-didanosine-containing regimen who lost limb fat over time (gain of 1.7% versus loss of 26.4%, p value not reported) [@pone.0063623-Dube2].

Unboosted atazanavir was associated with significant reduction in limb fat at 96 weeks, while there was no significant change in limb fat in the ritonavir-boosted atazanavir arm (both arms were on stavudine and lamivudine) [@pone.0063623-McComsey2]. The proportion of participants with ≥20% loss in limb fat was significantly greater in the unboosted atazanavir arm at 96 weeks [@pone.0063623-McComsey2]. However, there were no significant between-group differences in absolute change from baseline in SAT or limb fat with ritonavir-boosted versus unboosted atazanavir [@pone.0063623-McComsey2]. There were no significant between-group differences in absolute change from baseline in SAT or limb fat in a study comparing ritonavir-boosted tipranavir (at the registered dose) with ritonavir-boosted lopinavir [@pone.0063623-Carr2].

In the one study that compared raltegravir with efavirenz, average gains in limb fat over time and the incidence of lipoatrophy were similar in both groups [@pone.0063623-Lennox1].

### Fat gain: changes in trunk fat or VAT with different antiretroviral regimens {#s3d3}

In general, participants randomised to different ART regimens gained similar amounts of trunk fat or VAT over time. The changes from baseline in trunk fat and VAT are summarised in [Tables 12](#pone-0063623-t012){ref-type="table"}, [13](#pone-0063623-t013){ref-type="table"}, [14](#pone-0063623-t014){ref-type="table"}, [15](#pone-0063623-t015){ref-type="table"}, [16](#pone-0063623-t016){ref-type="table"}.

10.1371/journal.pone.0063623.t012

###### Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: NRTI-containing regimens versus NRTI-sparing regimens.

![](pone.0063623.t012){#pone-0063623-t012-12}

  Study                           Measure             Arm                           Week 48 (n)                  p value             Week 96 (n)             p value
  ------------------------------ --------- ------------------------- ------------------------------------------ --------- --------------------------------- ---------
  [@pone.0063623-Kolta1]           TF^a^         LPVr+AZT+3TC                       −211 g (22)                   0.665               346 g (5)              \>0.05
                                               LPVr monotherapy                     −579 g (41)                                      −859 g (8)             
  [@pone.0063623-Negredo1]                                             Percentage of body fat, 0 & 48 wks:^b^                                               
                                   TF^a^     LPVr+ continue 2NRTIs               20.6; 22.6 (33^c^)                NR                    ND                    NA
                                                   NVP+LPVr                      22.5; 24.0 (33^c^)                                      ND                 
  [@pone.0063623-vanVonderen1]                                          Mean (95% CI) cm^2^, 0 & 48 wks:^e^                Mean (95% CI) cm^2^, 96 wks:^e^  
                                  VAT^d^         AZT+3TC+LPVr         100 (88 to 112); 104 (90 to 118) (22^c^)     NR             122 (108 to 135)             NR
                                                   NVP+LPVr           100 (89 to 111); 109 (96 to 122) (26^c^)                     111 (98 to 124)          
  [@pone.0063623-Tebas2]          VAT^a^    ABC+continue other ARVs                  −15% (43)                     0.1                   ND                    NA
                                                   LPVr+NVP                           −4% (47)                                           ND                 
  [@pone.0063623-Tebas1]           TF^a^         EFV+2NRTIs^f^                     133 g^g^ (25)                 \>0.05            −583 g^g^ (25)            \>0.05
                                                   LPVr+EFV                        −170 g^g^ (22)                                  −206 g^g^ (22)           
  [@pone.0063623-Valantin1]        TF^a^     DRVr+ continue 2NRTIs                   5.9% (74)                   \>0.05                  ND                    NA
                                               DRVr monotherapy                      7.6% (67)                                           ND                 

a\. median; b. absolute values at each time-point (change from baseline not reported); c. n at baseline (n at time-point not stated); d. mean; e. means (corrected for differences in baseline values) and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from baseline not reported); f. DDI+3TC or DDI+AZT or AZT+3TC or D4T+3TC or DDI+D4T; g. values derived from graph.

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; DRVr: ritonavir-boosted darunavir; EFV: efavirenz; LPVr: ritonavir-boosted lopinavir; NVP: nevirapine.

10.1371/journal.pone.0063623.t013

###### Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: PI versus NNRTI.

![](pone.0063623.t013){#pone-0063623-t013-13}

  Study                                           Measure              Arm                                   Week 48 (n)                        p value                  Week 96 (n)                   p value
  ---------------------------------------------- --------- --------------------------- ------------------------------------------------------- --------- -------------------------------------------- ---------
  [@pone.0063623-McComsey1]                        TF^a^    ATVr+(ABC+3TC or TDF+FTC)                      26.1%^b^ (105)                         NR                      36.5% (94)                    0.028
                                                            EFV+(ABC+3TC or TDF+FTC)                       20.4%^b^ (112)                                                21.1% (109)                  
                                                    VAT     ATVr+(ABC+3TC or TDF+FTC)                            NR                               NA      LR coefficient^c^ (ATVr vs EFV) 11.0 cm^2^    0.20
                                                            EFV+(ABC+3TC or TDF+FTC)                             NR                                                  95% CI −5.9 to 27.9              
  [@pone.0063623-Cameron1]                         TF^d^     LPVr+AZT+3TC or LPVr^e^                          6.9% (NR)                           NR                    13.8%^b^ (74)                  \>0.05
                                                                   EFV+AZT+3TC                               15.2% (NR)                                                 14.6%^b^ (32)                 
  [@pone.0063623-Jemsek1]                         VAT^a^           ATV+AZT+3TC          15.3 cm^2^ (62). 95% CI for difference: −10.4 to 12.6     NR                          ND                         NA
                                                                   EFV+AZT+3TC                             14.1 cm^2^ (46)                                                    ND                      
  [@pone.0063623-Dube1], [@pone.0063623-Dube2]    TF^d,f^   NFV+(AZT+3TC or DDI+D4T)                        8.3%^b^ (23)                          NR                    −6.8%^b^ (11)                    NR
                                                            EFV+(AZT+3TC or DDI+D4T)                        14.8%^b^ (26)                                               32.6%^b^ (16)                 

a\. mean; b. values derived from graph; c. adjusted for treatment allocation, sex, age, race, and baseline HIV RNA, CD4 count and BMI; d. median; e. LPVr monotherapy if virologically suppressed for 3 months; f. as treated analysis.

LR: linear regression; NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC: emtricitabine; LPVr: ritonavir-boosted lopinavir; NFV: nelfinavir; TDF: tenofovir.

10.1371/journal.pone.0063623.t014

###### Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: NRTI versus NRTI.

![](pone.0063623.t014){#pone-0063623-t014-14}

  Study                                           Measure                    Arm                      Week 48 (n)     p value                      Week 96 (n)                      p value
  ---------------------------------------------- --------- ---------------------------------------- ---------------- --------- --------------------------------------------------- ---------
  [@pone.0063623-McComsey1]                        TF^a^            ABC+3TC+(ATVr or EFV)            24.9%^b^ (107)     NR                       29.4%^b^ (102)                      0.76
                                                                    TDF+FTC+(ATVr or EFV)            21.6%^b^ (110)                              27.3%^b^ (101)                    
                                                    VAT             ABC+3TC+(ATVr or EFV)                  ND           NA      LR coefficient^c^ (ABC+3TC vs TDF+FTC) −5.3 cm^2^    0.52
                                                                    TDF+FTC+(ATVr or EFV)                  ND                                 95% CI −21.5 to 11.0                 
  [@pone.0063623-Podzamczer1]                      TF^a^                 ABC+3TC+EFV                       ND           NA                         1225 g (25)                       0.58
                                                                         D4T+3TC+EFV                       ND                                      996 g (32)                      
  [@pone.0063623-Moyle1]                           TF^a^    Switch AZT/D4T to ABC+cont. other ARVs     618 g (44)      0.97                            ND                             NA
                                                            Switch AZT/D4T to TDF+cont. other ARVs     607 g (49)                                      ND                          
                                                  VAT^a^    Switch AZT/D4T to ABC+cont. other ARVs    2 cm^2^ (44)     0.49                            ND                             NA
                                                            Switch AZT/D4T to TDF+cont. other ARVs   6.8 cm^2^ (49)                                    ND                          
  [@pone.0063623-Dube1], [@pone.0063623-Dube2]    TF^d,e^            DDI+D4T+(EFV or NFV)              9.8%b (42)       NR                        −0.7%^b^ (22)                       NR
                                                                     AZT+3TC+(EFV or NFV)              9.1%b (39)                                 13.6%^b^ (24)                    

a\. mean; b. values derived from graph; c. adjusted for treatment allocation, sex, age, race, and baseline HIV RNA, CD4 count and BMI; d. median; e. as treated analysis.

LR: linear regression; NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; ATVr: ritonavir-boosted atazanavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; FTC: emtricitabine; NFV: nelfinavir; TDF: tenofovir.

10.1371/journal.pone.0063623.t015

###### Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: PI versus PI.

![](pone.0063623.t015){#pone-0063623-t015-15}

  Study                        Measure         Arm         Week 48 (n)          p value          Week 96 (n)   p value
  --------------------------- --------- ----------------- ------------- ----------------------- ------------- ---------
  [@pone.0063623-McComsey2]     TF^a^     ATVr+D4T+3TC      12% (72)              NR              16% (55)     \>0.05
                                           ATV+D4T+3TC      15% (89)                              14% (67)    
                               VAT^a^     ATVr+D4T+3TC      28% (68)              NR              33% (56)     \>0.05
                                           ATV+D4T+3TC      34% (85)                              32% (62)    
  [@pone.0063623-Carr2]         TF^b^    TPVr100+TDF+3TC   −0.8% (46)    0.005 vs LPVr+TDF+3TC       ND          NA
                                         TPVr200+TDF+3TC   −0.7% (48)    0.02 vs LPVr+TDF+3TC        ND       
                                          LPVr+TDF+3TC      2.1% (45)                                ND       
                               VAT^b^    TPVr100+TDF+3TC   −6 cm2 (46)    0.4 vs LPVr+TDF+3TC        ND          NA
                                         TPVr200+TDF+3TC   −9 cm2 (48)   0.04 vs LPVr+TDF+3TC        ND       
                                          LPVr+TDF+3TC     −3 cm2 (45)                               ND       

a\. mean; b. median.

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ATV: atazanavir; ATVr: ritonavir-boosted atazanavir; D4T: stavudine; LPVr: ritonavir-boosted lopinavir; TDF: tenofovir; TPVr100: tipranavir/ritonavir 500/100 mg twice a day; TPVr200: tipranavir/ritonavir 500/200 mg twice a day.

10.1371/journal.pone.0063623.t016

###### Change from baseline in trunk fat (TF) on DEXA scan, and visceral adipose tissue (VAT) on CT scan: raltegravir versus efavirenz.

![](pone.0063623.t016){#pone-0063623-t016-16}

  Study                      Measure       Arm        Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------- --------- -------------- ------------- --------- ------------- ---------
  [@pone.0063623-Lennox1]     TF^a^    RAL+TDF +FTC   18.9% (40)    0.63^b^   21.6% (37)    0.71^b^
                                       EFV+TDF +FTC   22.6% (46)              25.5% (38)   

a\. mean; b. p value calculated by authors of this review.

Antiretrovirals: EFV: efavirenz; FTC: emtricitabine; RAL: raltegravir; TDF: tenofovir.

There were no significant between-group differences in changes from baseline in trunk fat or VAT in the six studies that compared NRTI-sparing and NRTI-containing regimens [@pone.0063623-Negredo1], [@pone.0063623-Kolta1], [@pone.0063623-Valantin1], [@pone.0063623-vanVonderen1], [@pone.0063623-Tebas1], [@pone.0063623-Tebas2], and in the four studies that compared different NRTI-containing regimens [@pone.0063623-McComsey1], [@pone.0063623-Podzamczer1], [@pone.0063623-Moyle1], [@pone.0063623-Dube2]. Similarly, there were no significant differences in the incidences of lipohypertrophy (defined as \>20% gain in trunk fat) [@pone.0063623-Kolta1], [@pone.0063623-Valantin1], [@pone.0063623-Cameron1].

The results of studies that compared PIs and NNRTIs were not consistent. One study found that participants who received ritonavir-boosted atazanavir had significantly greater increases in trunk fat at week 96 than those who received efavirenz (36.5% versus 21.1% respectively, p = 0.028) [@pone.0063623-McComsey1]. Another study found no significant changes at week 48 in VAT between those who received unboosted atazanavir compared with those who received efavirenz (15.3 cm^2^ versus 14.1 cm^2^ respectively, 95% confidence interval for the difference: −10.4 to 12.6 cm^2^) [@pone.0063623-Jemsek1]. There were no significant between-group differences in changes from baseline in trunk fat, or in incidence of lipohypertrophy in one study that compared ritonavir-boosted lopinavir and efavirenz [@pone.0063623-Cameron1]. One study found that participants who received efavirenz gained more trunk fat over time on average than those who received nelfinavir, however it was not reported whether or not the difference was statistically significant [@pone.0063623-Dube2].

There were no significant between-group changes from baseline in trunk fat or VAT in those who received ritonavir-boosted atazanavir compared with unboosted atazanavir in one study [@pone.0063623-McComsey2]. A study that compared ritonavir-boosted tipranavir and ritonavir-boosted lopinavir found small, but statistically significant between-group differences in changes from baseline in both trunk fat and VAT: those who received ritonavir-boosted tipranavir lost trunk fat over time, while those who received ritonavir-boosted lopinavir gained trunk fat over time [@pone.0063623-Carr2].

In the one study that compared raltegravir with efavirenz, gains in trunk fat over time were similar in both groups [@pone.0063623-Lennox1].

### Changes in limb fat and SAT after switching antiretroviral regimens {#s3d4}

In general, participants who were switched away from NRTI-containing, or more specifically thymidine analogue-containing, regimens gained limb fat over time, when compared with participants who continued NRTI- or thymidine analogue-containing regimens, who generally lost limb fat [@pone.0063623-Feeney1]--[@pone.0063623-Carr3], [@pone.0063623-Tebas2], [@pone.0063623-Milinkovic1].

There were no significant between-group differences in changes from baseline in limb fat or SAT in studies that switched to NNRTI- from PI-containing regimens [@pone.0063623-Ruiz1], to ritonavir-boosted atazanavir from other ritonavir-boosted PI regimens [@pone.0063623-Moyle2], or to raltegravir from PI regimens [@pone.0063623-Curran1].

Changes from baseline in limb fat, subcutaneous thigh fat and SAT are summarized in [Tables 17](#pone-0063623-t017){ref-type="table"}, [18](#pone-0063623-t018){ref-type="table"}, [19](#pone-0063623-t019){ref-type="table"}, [20](#pone-0063623-t020){ref-type="table"}, and [21](#pone-0063623-t021){ref-type="table"}.

10.1371/journal.pone.0063623.t017

###### Switching studies: change from baseline in subcutaneous thigh fat (STF) and subcutaneous adipose tissue (SAT) on CT scan: NRTI-containing regimens versus NRTI-sparing regimens.

![](pone.0063623.t017){#pone-0063623-t017-17}

  Study                        Measure             Arm             Week 24 (n)   p value    Week 48 (n)    p value    Week 96 (n)     p value
  --------------------------- --------- ------------------------- ------------- --------- --------------- --------- ---------------- ---------
  [@pone.0063623-Tebas2]       STF^a^    Cont AZT or D4T regimen    −3% (24)       NR           ND           NA            ND           NA
                                           Switch to LPVr+NVP        8% (40)                    ND                         ND        
  [@pone.0063623-Valantin2]    STF^b^       Cont NRTI regimen          ND          NA      0 cm^3^ (35)     0.004    11 cm^3^ (25)     0.001
                                           Switch to PI+NNRTI          ND                  42 cm^3^ (41)             120 cm^3^ (28)  
                               SAT^b^       Cont NRTI regimen          ND          NA      1 cm^3^ (35)     0.004    14 cm^3^ (23)     0.088
                                           Switch to PI+NNRTI          ND                  22 cm^3^ (39)             31 cm^3^ (30)   

a\. median; b. mean.

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: AZT: zidovudine; D4T: stavudine; LPVr: ritonavir-boosted lopinavir; NVP: nevirapine.

10.1371/journal.pone.0063623.t018

###### Switching studies: change from baseline in limb fat (LF) on DEXA scan: PI versus NNRTI.

![](pone.0063623.t018){#pone-0063623-t018-18}

  Study                    Measure             Arm            Week 24 (n)   p value   Week 48 (n)                p value                 Week 96 (n)   p value
  ----------------------- ---------- ----------------------- ------------- --------- ------------- ------------------------------------ ------------- ---------
  [@pone.0063623-Ruiz1]                                                                             Mean (95% CI) 0 & 48 wks (kg):^d^                 
                           LF ^a,b^      Cont PI+ 2NRTIs          ND          NA      NR (54^c^)    1.5 (1.3 to 1.8); 1.3 (1.1 to 1.6)       ND          NA
                                      Switch to NVP+DDI+D4T       ND                  NR (52^c^)    1.2 (1.1 to 1.4); 1.2 (1.1 to 1.4)       ND       

a\. mean; b. leg fat; c. n at baseline (n at time-point not stated); d. means and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from baseline not reported).

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: D4T: stavudine; DDI: didanosine; NVP: nevirapine.

10.1371/journal.pone.0063623.t019

###### Switching studies: change from baseline in limb fat (LF) on DEXA scan, and subcutaneous thigh fat (STF) and subcutaneous adipose tissue (SAT) on CT scan: NRTI versus NRTI.

![](pone.0063623.t019){#pone-0063623-t019-19}

  Study                      Measure              Arm               Week 24 (n)     p value                     Week 48 (n)                     p value   Week 96   p value
  ------------------------- ---------- ------------------------- ----------------- --------- ------------------------------------------------- --------- --------- ---------
  [@pone.0063623-Fisher1]     LF^a^        Cont AZT+3TC+EFV             ND            NA      −187 g (36). 95% CI for difference: 57 to 837 g    0.024      ND        NA
                                          Switch TDF+FTC+EFV            ND                                      261 g (38)                                  ND     
  [@pone.0063623-Tebas2]      STF^b^    Cont AZT or D4T regimen      −3% (24)         NR                            ND                            NA        ND        NA
                                         Switch AZT/D4T to ABC        0% (37)                                       ND                                      ND     
  [@pone.0063623-Carr3]       LF^a^     Cont AZT or D4T regimen    0.08 kg (56)      0.02                           ND                            NA        ND        NA
                                         Switch AZT/D4T to ABC     0.39 kg (50)                                     ND                                      ND     
                             STF^a,c^   Cont AZT or D4T regimen   −1.2 cm^2^ (56)    0.01                           ND                            NA        ND        NA
                                         Switch AZT/D4T to ABC    3.3 cm^2^ (50)                                    ND                                      ND     
                              SAT^a^    Cont AZT or D4T regimen   −1.2 cm^2^ (56)    0.001                          ND                            NA        ND        NA
                                         Switch AZT/D4T to ABC    13.9 cm^2^ (50)                                   ND                                      ND     
  [@pone.0063623-Feeney1]     SAT^b^         Cont AZT+3TC          −2.7%^d^(NR)       NR                       −2.7%^d^ (59)                     0.03       ND        NA
                                           Switch to TDF+FTC       2.1%^d^ (NR)                                1.6%^d^ (66)                                 ND     
                              LF^b^          Cont AZT+3TC          3.2%^d^ (NR)       NR                       1.1%^d^ (59)                       0.5       ND        NA
                                           Switch to TDF+FTC       3.9%^d^ (NR)                                5.2%^d^ (66)                                 ND     

a\. mean; b. median; c. right thigh; d. values derived from graph.

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; EFV: efavirenz; FTC: emtricitabine; TDF: tenofovir.

10.1371/journal.pone.0063623.t020

###### Switching studies: change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: PI versus PI.

![](pone.0063623.t020){#pone-0063623-t020-20}

  Study                     Measure           Arm            Week 24 (n)   p value   Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------ --------- ---------------------- ------------- --------- ------------- --------- ------------- ---------
  [@pone.0063623-Moyle2]     LF^a^    Continue PIr +2NRTIs       ND          NA      −3.6% (54)     0.15     −6.1% (54)     0.17
                                       Switch PIr to ATVr        ND                  0.9% (112)              −0.8% (112)  
                            SAT^a^    Continue PIr +2NRTIs       ND          NA      −5.9% (59)     0.16     −9.7% (59)      0.6
                                       Switch PIr to ATVr        ND                  −2.1% (108)             −3.5% (108)  

a\. mean.

NA: not applicable; ND: not done.

Antiretrovirals: ATVr: ritonavir-boosted atazanavir; PIr: ritonavir-boosted PI.

10.1371/journal.pone.0063623.t021

###### Switching studies: change from baseline in limb fat (LF) on DEXA scan and subcutaneous adipose tissue (SAT) on CT scan: PI versus raltegravir.

![](pone.0063623.t021){#pone-0063623-t021-21}

  Study                      Measure         Arm          Week 24 (n)   p value   Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------- --------- ------------------ ------------- --------- ------------- --------- ------------- ---------
  [@pone.0063623-Curran1]     LF^a^    Cont PI regimen        ND          NA      171 g (35)     0.791        ND          NA
                                       Switch PI to RAL       ND                   32 g (39)                  ND       
                             SAT^a^    Cont PI regimen        ND          NA       3.6% (35)     0.496        ND          NA
                                       Switch PI to RAL       ND                  −1.9% (39)                  ND       

a\. median.

NA: not applicable; ND: not done; RAL: raltegravir.

### Changes in trunk fat or VAT after switching antiretroviral regimens {#s3d5}

In general, participants who were switched away from NRTI-containing regimens, or from thymidine analogue-containing regimens, had similar increases in trunk fat over time to those who continued NRTI- or thymidine analogue-containing regimens [@pone.0063623-Valantin2], [@pone.0063623-Carr3].

There were no significant between-group differences in changes from baseline in trunk fat or VAT in studies that switched to NNRTI- from PI-containing regimens [@pone.0063623-Ruiz1], to ritonavir-boosted atazanavir from other ritonavir-boosted PI regimens [@pone.0063623-Moyle2], or to raltegravir from PI regimens [@pone.0063623-Curran1].

Changes from baseline in trunk fat and VAT are summarised in [Tables 22](#pone-0063623-t022){ref-type="table"}, [23](#pone-0063623-t023){ref-type="table"}, [24](#pone-0063623-t024){ref-type="table"}, [25](#pone-0063623-t025){ref-type="table"}, and [26](#pone-0063623-t026){ref-type="table"}.

10.1371/journal.pone.0063623.t022

###### Switching studies: change from baseline in visceral adipose tissue (VAT) on CT scan: NRTI-containing versus NRTI-sparing regimens.

![](pone.0063623.t022){#pone-0063623-t022-22}

  Study                        Measure          Arm           Week 24 (n)   p value   Week 48 (n)    p value    Week 96 (n)    p value
  --------------------------- --------- -------------------- ------------- --------- -------------- --------- --------------- ---------
  [@pone.0063623-Valantin2]    VAT^a^    Cont NRTI regimen        ND          NA      5 cm^3^ (35)    0.987    17 cm^3^ (23)    0.566
                                         Switch to PI+NNRTI       ND                  7 cm^3^ (39)             6 cm^3^ (30)   

a\. mean.

NA: not applicable; ND: not done.

10.1371/journal.pone.0063623.t023

###### Switching studies: change from baseline in trunk fat (TF) on DEXA scan: PI versus NNRTI.

![](pone.0063623.t023){#pone-0063623-t023-23}

  Study                    Measure            Arm             Week 24   p value   Week 48 (n)                p value                 Week 96   p value
  ----------------------- --------- ------------------------ --------- --------- ------------- ------------------------------------ --------- ---------
  [@pone.0063623-Ruiz1]                                                                         Mean (95% CI) 0 & 48 wks (kg):^c^             
                           TF ^a^       Cont PI+ 2NRTIs         ND        NA      NR (54^b^)    7.8 (6.9 to 8.7); 8.0 (6.9 to 9.1)     ND        NA
                                     Switch to NVP +DDI+D4T     ND                NR (52^b^)    6.3 (5.7 to 6.9); 5.9 (5.2 to 6.7)     ND     

a\. mean; b. n at baseline (n at time-point not stated); c. means and 95% confidence intervals (calculated by the authors of this review) at each time-point (change from baseline not reported).

NA: not applicable; ND: not done; NR: not reported.

Antiretrovirals: D4T: stavudine; DDI: didanosine; NVP: nevirapine.

10.1371/journal.pone.0063623.t024

###### Switching studies: change from baseline in trunk fat (TF) on DEXA scan and visceral adipose tissue (VAT) on CT scan: NRTI versus NRTI.

![](pone.0063623.t024){#pone-0063623-t024-24}

  Study                      Measure             Arm               Week 24 (n)     p value   Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------- --------- ------------------------- ----------------- --------- ------------- --------- ------------- ---------
  [@pone.0063623-Fisher1]     TF^a^       Cont AZT+ 3TC+EFV            ND            NA         358 g      \>0.05        ND          NA
                                         Switch TDF+ FTC+EFV           ND                       130 g                    ND       
  [@pone.0063623-Carr3]       TF^a^    Cont AZT or D4T regimen     0.8 kg (56)      0.31         ND          NA          ND          NA
                                       Switch AZT/ D4T to ABC      1.4 kg (50)                   ND                      ND       
                             VAT^a^    Cont AZT or D4T regimen   −1.3 cm^2^ (56)    0.07         ND          NA          ND          NA
                                       Switch AZT/ D4T to ABC    1.2 cm^2^ (50)                  ND                      ND       

a\. mean.

NA: not applicable; ND: not done.

Antiretrovirals: 3TC: lamivudine; ABC: abacavir; AZT: zidovudine; D4T: stavudine; DDI: didanosine; EFV: efavirenz; TDF: tenofovir.

10.1371/journal.pone.0063623.t025

###### Switching studies: change from baseline in trunk fat (TF) on DEXA scan and visceral adipose tissue (VAT) on CT scan: PI versus PI.

![](pone.0063623.t025){#pone-0063623-t025-25}

  Study                     Measure           Arm            Week 24 (n)   p value   Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------ --------- ---------------------- ------------- --------- ------------- --------- ------------- ---------
  [@pone.0063623-Moyle2]     TF^a^    Continue PIr +2NRTIs       ND          NA      −1.8% (57)     0.14     −3.6% (57)     0.14
                                       Switch PIr to ATVr        ND                  2.6% (112)              1.6% (112)   
                            VAT^a^    Continue PIr +2NRTIs       ND          NA      −0.5% (59)     0.27      1.6% (59)     0.68
                                       Switch PIr to ATVr        ND                  4.6% (108)              3.4% (108)   

a\. mean.

NA: not applicable; ND: not done.

Antiretrovirals: ATVr: ritonavir-boosted atazanavir; PIr: ritonavir-boosted PI.

10.1371/journal.pone.0063623.t026

###### Switching studies: change from baseline in trunk fat (TF) on DEXA scan and visceral adipose tissue (VAT) on CT scan: PI versus raltegravir.

![](pone.0063623.t026){#pone-0063623-t026-26}

  Study                      Measure         Arm          Week 24 (n)   p value   Week 48 (n)   p value   Week 96 (n)   p value
  ------------------------- --------- ------------------ ------------- --------- ------------- --------- ------------- ---------
  [@pone.0063623-Curran1]     TF^a^    Cont PI regimen        ND          NA      382 g (35)     0.729        ND          NA
                                       Switch PI to RAL       ND                  −28 g (39)                  ND       
                             VAT^a^    Cont PI regimen        ND          NA      11.9% (35)     0.936        ND          NA
                                       Switch PI to RAL       ND                  12.8% (39)                  ND       

a\. median.

NA: not applicable; ND: not done; RAL: raltegravir.

Discussion {#s4}
==========

We found overwhelming evidence that lipoatrophy is an antiretroviral adverse drug reaction. Subcutaneous fat volumes are considerably lower in patients on ART than in controls, subcutaneous fat loss progresses on ART, is associated with stavudine and zidovudine use, and partially reverses after switching to abacavir, tenofovir or an NRTI-sparing regimen. By contrast, central fat gain does not appear to be an antiretroviral adverse drug reaction. Visceral and trunk fat volume is no different in women on ART compared with control women, and is less in men on ART than in control men. Visceral fat accumulates at the same rate in patients on ART and controls. Finally, central fat gain generally occurs at similar rates in HIV-infected patients randomised to different ART regimens, is not associated with any specific antiretroviral drug or drug class, and does not reverse on switching antiretrovirals. We believe that this evidence indicates that central fat gain is a consequence of treating HIV infection, which normalizes the concentrations of inflammatory markers such as TNF-α (tumour necrosis factor alpha) that are known to cause wasting [@pone.0063623-Haissman1]. Lipoatrophy occurring together with central fat gain results in an unusual appearance, which may have persuaded clinicians that the fat gain is an antiretroviral adverse drug reaction. The fact that diet and exercise have been shown to improve central fat gain in patients on antiretroviral therapy provides some support for our conclusion that it is a consequence of lifestyle [@pone.0063623-Thoni1]--[@pone.0063623-Driscoll1].

Efavirenz is associated with a higher risk of limb fat loss than PIs when combined with NRTIs that cause fat loss. A possible explanation for this observation is that the anti-apoptotic properties of PIs partially ameliorate the loss of adipocytes by increased apoptosis that is induced by NRTIs [@pone.0063623-Vlahakis1]. The observation that unboosted atazanavir, which is a non-peptidomimetic PI that does not have anti-apoptotic properties, is associated with more limb fat loss than ritonavir (a peptidomimetic PI)-boosted atazanavir supports this hypothesis. Alternatively, efavirenz may increase the adipocyte toxicity of thymidine analogue NRTIs. Efavirenz has been shown to be more toxic to adipocytes and to release more inflammatory cytokines than lopinavir-ritonavir [@pone.0063623-GallegoEscuredo1]. Furthermore, efavirenz also displays mitochondrial toxicity in hepatocytes [@pone.0063623-Apostolova1]; although we could find no data to support this, it is possible that it has a similar effect on adipocytes. Mitochondrial toxicity is thought to be a key mechanism of thymidine analogue-induced lipoatrophy [@pone.0063623-McComsey1].

Our study has several limitations. First, many of the studies that reported objective measures of fat redistribution by ART regimen were convenience sub-studies of randomised controlled trials, therefore patients undergoing DEXA and/or CT scans were not randomised. However, fat distribution sub-studies generally reported that the characteristics of the patients undergoing imaging of fat tissue were not different from the parent trial population. Many RCTs were powered according to efficacy end-points, and not for objective measures of fat distribution. Second, many studies reported only summary statistics and different outcome measures were reported, which prevented us from pooling data from different studies. Third, some studies did not report statistical analyses of changes in body fat distribution by study arm. Fourth, we were unable to assess the role of older protease inhibitors (other than nelfinavir) or nevirapine in fat redistribution as no studies with those antiretrovirals fulfilled our inclusion criteria. Fifth, we found only one study that compared fat changes over time in patients on ART and HIV-infected controls that was conducted in the United States. This limits our ability to generalise findings to other populations. Finally, we cannot exclude the causative role of specific antiretrovirals in focal forms of fat gain, such as buffalo humps, as the included studies reported trunk or visceral fat changes only.

In conclusion, our systematic review supports the hypothesis that peripheral lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. Lipoatrophy can be avoided and at least partially reversed by avoiding thymidine analogue nucleoside reverse transcriptase inhibitors. Central fat gain appears to be a consequence of treating HIV-infection, and reflects patterns of fat gain seen in the HIV-uninfected population.

Supporting Information {#s5}
======================

###### 

**Excluded studies.**

(DOCX)

###### 

Click here for additional data file.

###### 

**Risk of bias.**

(DOCX)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no conflicts of interest exist.

[^2]: Conceived and designed the experiments: GM RdW KC. Performed the experiments: RdW KC GM. Analyzed the data: RdW KC. Contributed reagents/materials/analysis tools: GM RdW KC. Wrote the paper: RdW KC GM.
